NCT04514484 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT04514484
Title	Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
Recruitment	Active, not recruiting
Gender	both
Phase	Phase I
Variant Requirements	No
Sponsors	National Cancer Institute (NCI)
Indications	Advanced Solid Tumor prostate carcinoma hepatocellular carcinoma transitional cell carcinoma differentiated high-grade thyroid carcinoma lung small cell carcinoma renal cell carcinoma medullary thyroid carcinoma lung non-small cell carcinoma Kaposi's sarcoma ovarian cancer head and neck cancer triple-receptor negative breast cancer melanoma
Therapies	Cabozantinib + Nivolumab
Age Groups:	adult \| senior
Covered Countries	USA

Facility	City	State	Zip	Country	Details
Northwestern University	Chicago	Illinois	60611	United States	Details
Montefiore Medical Center-Einstein Campus	The Bronx	New York	10461	United States	Details
University of Pittsburgh Cancer Institute (UPCI)	Pittsburgh	Pennsylvania	15232	United States	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT04514484Clinical Trial Detail